Exploring the cxcr3 chemokine receptor with small-molecule antagonists and agonists

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3. This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.

Original languageEnglish
Pages (from-to)119-185
Number of pages68
JournalTopics in Medicinal Chemistry
Volume14
DOIs
Publication statusPublished - 2015

Fingerprint

Chemokine Receptors
Ligands
Chemokines
Mutagenesis
CXCR Receptors
CXCR3 Receptors
Molecular Computers
Pharmacology
Inflammation
Peptidomimetics
Immune System Diseases
Structure-Activity Relationship
Inflammatory Bowel Diseases
Chronic Obstructive Pulmonary Disease
Multiple Sclerosis
Rheumatoid Arthritis
Atherosclerosis
Therapeutics
Animal Models
Binding Sites

Keywords

  • Allosteric modulation
  • C-X-C chemokine receptor type 3
  • G protein-coupled receptor
  • GPCR crystal structure
  • Homology modeling
  • Mutagenesis studies
  • Receptor-ligand interactions
  • Small-molecule agonist
  • Small-molecule antagonist
  • Structure-activity relationship
  • Structure-function relationship

Cite this

@article{29b3436717b04deda19cf926e0093ba3,
title = "Exploring the cxcr3 chemokine receptor with small-molecule antagonists and agonists",
abstract = "CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3. This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.",
keywords = "Allosteric modulation, C-X-C chemokine receptor type 3, G protein-coupled receptor, GPCR crystal structure, Homology modeling, Mutagenesis studies, Receptor-ligand interactions, Small-molecule agonist, Small-molecule antagonist, Structure-activity relationship, Structure-function relationship",
author = "M. Wijtmans and Danny Scholten and Wouter Mooij and Smit, {Martine J.} and {De Esch}, {Iwan J P} and {de Graaf}, C. and Rob Leurs",
year = "2015",
doi = "10.1007/7355_2014_75",
language = "English",
volume = "14",
pages = "119--185",
journal = "Topics in Medicinal Chemistry",
issn = "1862-2461",
publisher = "Springer Verlag",

}

Exploring the cxcr3 chemokine receptor with small-molecule antagonists and agonists. / Wijtmans, M.; Scholten, Danny; Mooij, Wouter; Smit, Martine J.; De Esch, Iwan J P; de Graaf, C.; Leurs, Rob.

In: Topics in Medicinal Chemistry, Vol. 14, 2015, p. 119-185.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Exploring the cxcr3 chemokine receptor with small-molecule antagonists and agonists

AU - Wijtmans, M.

AU - Scholten, Danny

AU - Mooij, Wouter

AU - Smit, Martine J.

AU - De Esch, Iwan J P

AU - de Graaf, C.

AU - Leurs, Rob

PY - 2015

Y1 - 2015

N2 - CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3. This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.

AB - CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3. This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.

KW - Allosteric modulation

KW - C-X-C chemokine receptor type 3

KW - G protein-coupled receptor

KW - GPCR crystal structure

KW - Homology modeling

KW - Mutagenesis studies

KW - Receptor-ligand interactions

KW - Small-molecule agonist

KW - Small-molecule antagonist

KW - Structure-activity relationship

KW - Structure-function relationship

UR - http://www.scopus.com/inward/record.url?scp=84924403959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924403959&partnerID=8YFLogxK

U2 - 10.1007/7355_2014_75

DO - 10.1007/7355_2014_75

M3 - Article

VL - 14

SP - 119

EP - 185

JO - Topics in Medicinal Chemistry

JF - Topics in Medicinal Chemistry

SN - 1862-2461

ER -